Before you add anything, audit everything.

Patients arrive with protocols assembled from multiple sources: a TRT clinic, an online peptide community, a naturopath, a direct-to-consumer lab service. The stack audit is the clinical framework for evaluating what is there before deciding what to change.

I. Why the audit comes before the add.

Polypharmacy in optimization medicine is common and underappreciated. Patients frequently combine compounds from multiple prescribers without any single clinician holding the complete picture. A TRT prescription from one provider, a peptide stack from a telehealth platform, and supplements from a wellness influencer may all be running simultaneously. No one has mapped the intersection.

The consequence is predictable: pharmacodynamic interactions that blunt or amplify intended effects, redundant mechanisms consuming budget without additional benefit, dangerous gaps in baseline monitoring, and compounds placed in the wrong tier sequence. Optimization layered on a broken foundation does not compound the benefit. It compounds the problem.

II. The seven audit domains.

Map the patient's current status across seven domains before making any recommendation to add, remove, or modify.

• Foundation labs. HOMA-IR, fasting insulin, fasting glucose, HbA1c, full thyroid panel (TSH, fT4, fT3, rT3), 4-point cortisol, CBC with differential, CMP, lipid panel, hs-CRP. These are the floor. Without them, every clinical inference is a guess.
• Hormone baseline. Total testosterone, free testosterone, SHBG, estradiol (sensitive LC-MS/MS method), LH, FSH, prolactin, DHEA-S, IGF-1. Hormone status dictates how every subsequent compound will perform.
• Body composition. Lean mass percentage, visceral adipose tissue estimate (DEXA preferred where available), waist circumference, and BMI in context. The goal is not the number but the trajectory and what it implies about metabolic health.
• Current compounds. Complete list including dose, route, frequency, duration on compound, prescribing source, and what monitoring, if any, is in place. Every item on this list, including supplements and over-the-counter compounds, must be captured.
• Sleep architecture. Duration, continuity, STOP-BANG screen for obstructive sleep apnea, and subjective cortisol awakening response (CAR). Sleep is a Tier 1 physiological input. A protocol running on fragmented sleep is running at a structural disadvantage.
• Training and nutrition. Resistance training frequency and volume, protein intake estimation in g/kg/day, and caloric context: surplus, maintenance, or deficit. The anabolic signal from a protocol is only as strong as the training and nutritional substrate it has to work with.
• Subjective outcomes. Energy, libido, body composition trend, cognitive clarity, mood stability, recovery rate. The patient's own assessment of what is and is not working is a primary data point, not a secondary one.

III. Red flags that require resolution before continuation.

Certain findings in the audit require active resolution before any new compound is introduced or any existing compound is continued without modification.

HOMA-IR above 2.5: insulin resistance must be addressed before adding further anabolic compounds. The anabolic signal cannot operate efficiently in an insulin-resistant environment. Address the metabolic floor first. verified [III]

Hematocrit above 54%: requires evaluation and a documented management plan before TRT continuation. This is a cardiovascular risk threshold, not a monitoring curiosity. verified [I]

Free T3 below 3.0 pg/mL: thyroid tier needs attention. Optimization compounds perform poorly in a low thyroid state. Peripheral conversion, not just TSH, must be assessed. verified

4-point cortisol pattern flat or inverted: HPA dysregulation. A flat or inverted diurnal curve signals adrenal dysregulation that will blunt the benefit of nearly every compound in an optimization stack. Address before expanding. verified [II]

No baseline labs before initiating TRT or GH secretagogues: reconstruct the best available baseline from prior records, document the gap explicitly, and establish a current baseline before proceeding. The absence of a baseline is a clinical liability, not just an inconvenience.

IV. Identifying the highest-leverage gap.

After mapping all seven domains, rank deficiencies by their impact on protocol performance. Not all gaps are equal. The tier framework:

Tier 1 (fix first): insulin resistance, HPA dysregulation, thyroid dysfunction, sleep-disrupting obstructive sleep apnea. These conditions undermine every downstream intervention. Adding an anabolic compound over an unresolved Tier 1 gap is not additive. It is noise over noise.

Tier 2 (fix concurrently): protein floor below 1.6 g/kg/day, training volume insufficient to provide meaningful anabolic stimulus, vitamin D deficiency (below 40 ng/mL), magnesium deficiency. These are not optional refinements. They are structural inputs that determine protocol ceiling.

Tier 3 (optimize after Tier 1 and Tier 2 are addressed): peptide timing, GH secretagogue dose titration, estradiol fine-tuning, advanced longevity compounds. These are high-value interventions on a solid foundation. They are marginal additions to a broken one.

V. The interaction check.

Once the full compound list is mapped, a pharmacodynamic interaction check is mandatory. Cross-reference the complete stack for the following patterns, and document the review as part of the audit record. verified

GH secretagogues and metformin: AMPK activation from metformin blunts GH pulse amplitude. The interaction is mechanistically established. Either accept the tradeoff consciously or sequence appropriately. verified [IV]

Anastrozole and low-carbohydrate diet: compounding rT3 elevation risk. Low-carbohydrate dietary patterns can already suppress T3 conversion. Adding aromatase inhibition in this context requires thyroid monitoring.

High-dose vitamin D without K2: calcium dysregulation risk. D3 without K2 at supplemental doses can promote arterial calcium deposition. These are co-factors, not interchangeable alternatives.

Multiple AMPK activators simultaneously (metformin, berberine, MOTS-c): additive effect on glucose lowering. Monitor glucose closely. The combination is not contraindicated but requires active awareness. verified [IV]

Thymosin alpha-1 and active immunosuppressive therapy: absolute hold. Thymosin alpha-1 is an immune modulator. Its use alongside active immunosuppression requires specialist oversight and documented clinical rationale. verified

VI. The audit output.

The stack audit produces a written clinical assessment. That document includes: the verified current compound list, lab status by each of the seven domains, a ranked gap list, interaction flags, recommended changes in priority order, and a forward monitoring plan. It is not a verbal summary. It is a written record.

This document is the foundation for every subsequent clinical conversation with the patient. Without it, every follow-up visit restarts from ambiguity rather than building from a verified baseline.

Review at 90-day intervals at minimum. Update the compound list at every visit. Physiology is not static. A protocol that was correctly sequenced at month three may be incomplete, excessive, or incorrectly prioritized at month twelve.

THE PIVOTAL PROTOCOL is an intelligence and education layer, not a prescriber. The frameworks described here are derived from published literature and from Pivotal's own protocol design history. Every clinical decision belongs to a licensed physician with full knowledge of the case. Begin a conversation. Do not begin self-administration from a website.